Received Jul 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Can not breath; my eyes are swollen and teary; my eyes are swollen and teary; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of difficulty breathing in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced difficulty breathing (Verbatim: Can not breath), eye swelling (Verbatim: my eyes are swollen and teary) and eyes tearing (Verbatim: my eyes are swollen and teary). The outcome of the difficulty breathing, eye swelling and eyes tearing were not reported. It was unknown if the reporter considered the difficulty breathing, eye swelling and eyes tearing to be related to Arexvy. It was unknown if the company considered the difficulty breathing, eye swelling and eyes tearing to be related to Arexvy. Additional Information: GSK Receipt Date: 17-JUN-2025 The patient reporter after receiving Arexvy vaccine, could not breath, all stuffed op, eyes were swollen and teary.